1

CURRICULUM VITAE

Dr. Ottavio Arancio 2700 Broadway Apt 5H New York, NY 10025

(646) 209-1335 oa1@columbia.edu

Date of Preparation: April 12, 2016

Personal Data: Name: Ottavio Arancio Birthdate: August 8, 1957 Birthplace: Siracusa, Italy Citizenship: U.S., Italian Work Experience 05/2010 - Present Dept of Pathology and Cell Biology & Taub Institute for

Research on Alzheimer’s Disease and the Aging Brain, Columbia University, Tenureship, New York, NY

05/2009 - Present Dept of Pathology and Cell Biology & Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia Stem Cell Initiative, Columbia University, Associate Professor, New York, NY

02/2004 - 05/2008 Dept of Pathology and Cell Biology & Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, Assistant Professor, New York, NY

02/2002 - 02/2003 Department of Surgery, Columbia University, Adjunct Assistant Professor, New York, NY

02/2002 - 02/2004 Tenure NKI 02/2002 - 02/2004 Dept of Physiol & Neurosci., NYU School of Medicine, New York 10/2000 - 02/2004 Research Scientist VI/Assistant Professor, Dementia Research Center,

Dept. of Psychiatry and Silberstein Institute for Aging and Dementia, NKI/NYU School of Medicine, Assistant Professor, New York, NY

12/1998 - 10/2000 Department of Anatomy & Cell Biology, SUNY-HSCB, Assistant Professor, New York, NY

Training Clinical 10/1981 - 09/1986 Institute of Neurology, University of Verona, Resident Neurology,

Verona, Italy Research 01/1976 - 09/1980 Institute of Physiology, University of Pisa, Internship, Pisa, Italy 10/1986 - 09/1987 Neurological Institute, University of Verona, Ph.D. Student, Verona,

Italy 09/1987 - 03/1990 Department of Physiology & Cell Biophysics, Columbia University,

Research Fellow, New York, NY 04/1990 - 05/1991 Institute of Physiology, University of Verona, Research Fellow, Verona,

Italy 06/1991 - 09/1991 Center for Neurobiology and Behavior, Columbia University,

Research Fellow, New York, NY 09/1991 - 08/1992 Laboratoire de Neurobiologie Cellulaire, Pasteur Institute, Research

Scientist, Paris, France

2

09/1992 - 03/1995 Ctr for Neurobiology & Behavior , Columbia University, Post-doctoral Research Fellow, New York, NY

04/1995 - 03/1996 Ctr for for Neurobiology and Behavior, Columbia University, Post-doctoral Research Scientist, New York, NY

04/1996 - 12/1998 Center for Neurobiology and Behavior, Columbia University, Associate Research Scientist, New York, NY

Education 10/1975 - 07/1981 University of Pisa School of Medicine, M.D., cum laude, Thesis title: On

the role of NGF in the development of primary sensory neurons. Pisa, Italy.

10/1985 - 07/1990 University of Verona, Ph.D., Neuroscience, Thesis title: Excitatory aminoacid receptor mapping on rat spinal cord neurons in culture. Sponsor: H. Terzian. Citation of publication: Italian National Libraries, Florence and Rome Verona, Italy.

Licensure and Certification

10/1986 Board Certified in Neurology, cum laude, Neurological Institute,

University of Verona, Verona, Italy

Honors 1987 G. Moruzzi Fellowship, Fidia Research Foundation, Washington, D.C., USA 1990 Anna Villa Rusconi Foundation Prize, Varese, Italy 1990 Fellowship, Fidia SPA, Abano Terme, Italy 1991 Fellowship, Fidia SPA, Abano Terme, Italy 1991 INSERM Poste vert Fellowship, Paris, France 1994 Fellowship, University of Bologna, Bologna, Italy 2001-2003 Whitehead Fellowship 2001-2004 Speaker’s Fund for Biomedical Research 2004-2006 Investigator Initiated Research Award 2007 AHAF, Centennial Award 2007 Alzheimer’s Association, Zenith Award 2008 Margaret Cahn Research Award 2010 Edward N. and Della L. Thome Memorial Foundation, Award

Invited Lectures

Gordon Research Conference on “Neurobiology of Brain Disorders”, Girona, Spain (2014)

Workshop, The Future of Research and Clinical Applications in Neuroscience, Genova Italy,

(2014)

Symposium, Italian Embassy, Washington, USA (2013)

Symposium, DOD, Fort Dietrick, MD, USA (2013) Symposium, Pharmaceutical Society of Guizhou, Guizhou, China (2013)

Symposium, SINDEM, Perugia, Italy (2013)

Symposium, Italian Society of Pharmachology, Turin, Italy (2013)

Lecturing, Neuroscience course, New York Poly, Brooklyn, New York, USA (2013-2014)

Symposium, Society for Neuroscience, New Orleans, (2012)

Plenary Lecture, UK Alzheimer Association Meeting (2012)

Lecture, University La Sapienza, Rome, Italy (2012)

FIMMG meeting, Siracusa, Italy (2012)

3

DZNE-GIND Workshop, “Synaptic Pathophysiology and Neurodegenerative Disease”, Bonn,

Germany (2012)

Lecturing, Electrophysiology course, University of Pavia/Polytechnic University of Milan, Pavia,

Italy (2012)

ACNP Meeting, Waikoloa Beach, Hawaii (2011)

Inaugural International Alzheimer’s Symposium, Houston (2011)

XXIX Congresso Nazionale ONAV, Siracusa, Italy (2011)

International Symposium on Protein Phosphorylation in Neurodegenerative diseases, Valencia,

Spain (2010)

Keystone Symposia, Alzheimer’s disease Beyond Aβ, Copper Mountain (2010)

ADC Director Meeting, Baltimore (2010)

XIII National Congress of the Italian Society for Neuroscience, Milan, Italy (2009)

The 32nd Annual Meeting the Japan Neuroscience Society, Nagoya, Japan (2009)

European Calcium Society Workshop on “Annexins, targets and alcium-binding proteins in

pathology”, Smolenice, Slovakia (2009)

Plenary Talk, 9TH International Conference on Alzheimer’s Disease Drug Discovery, New York

(2008)

ICNBD2008, Seoul, Korea (2008)

11th ICAD conference, Symposium, Chicago (2008)

Alzheimer’s Disease: From Molecular Mechanisms to Drug Discovery. Punta Cana, Dominican

Republic (2007)

NIA AD Research Meeting, Washington (2007)

NIH, NIA Bethesda, (2007)

Neuroscience Meeting, Minisymposium, San Diego (2007)

7th International Conference on Alzheimer’s Disease Drug Discovery, NYC, New York (2006)

3rd Annual Phosphodiesterases in Drug Discovery & Development, Cherry Hill, NJ (2005)

6th International Conference on Alzheimer’s Disease Drug Discovery, NYC, New York (2005)

New York Academy of Science (2004)

5th International Conference on Alzheimer’s Disease Drug Discovery, NYC, New York (2004)

4th International Conference on Alzheimer’s Disease Drug Discovery, NYC, New York (2003)

3rd International Conference on Alzheimer’s Disease Drug Discovery, NYC, New York (2002)

Rockefeller University, New York Alzheimer Disease Research Society, New York (2002).

Annual Meeting Italian Society for Neuroscience (Italy) (1990).

Invited Seminars

University of Vienna, Vienna, Austria (2015)

AbbVie, Ludwigshafen, Germany (November 2014)

University of Catania, Catania, Italy (2014)

Northwestern University, Chicago, USA (2014)

NYU, New York, USA (2014)

AbbVie (former Abbott), Ludwigshafen, Germany (August 2014)

Fondazione Santa Lucia, Tor Vergata University, Rome Italy (2013)

University of Newcastle, Newcastle, Australia (2013)

Beijing Normal University, Beijing, China (2013)

University of Genova, Genova, Italy (2013)

4

University of Pavia, Pavia, Italy (2012)

University Cattolica, Rome, Italy (2012)

Temple University, Philadelphia, PA (2012)

New York Academy of Science in New York, NYC, NY (2011)

Takeda, Chicago, IL (2011)

Hunter College, NYC, NY (2011)

Mt. Sinai, New York, NY (2011)

Broad Institute, Boston, MS (2010)

Burke Institute, Tarrytown, NY (2010)

Mayo Clinic, Jacksonville, FL (2010)

University of Tokyo, Tokyo, Japan (2009)

RIKEN Institute, Tokyo, Japan (2009)

UTHSCSA, Dept of Physiology, San Antonio, TX (2009)

University of Illinois Chicago, Dept of Med. Chem. and Pharm., Chicago, IL (2009)

Columbia University, Dept of Pathology and Cell Biology, NYC, NY (2009) Northwestern Univerisity, Dept of Neurobiol. and Physiol., Chicago, IL (2009)

New York University, Dept of Biochemistry, NYC, NY (2009)

Psychogenics, Tarrytown, NY (2008)

Nathan Kline Institute, Dementia Res. Program, Orangeburg, NY (2008)

University of Geneva, Switzereland (2008) University of Texas at Dallas, Dept of Biology, Dallas, TX (2008)

Drexel University College of Medicine, Philadelphia, PA (2008)

SUNY at Buffalo SMBS, Dept. Physiology & Biophysics, Buffalo (2007)

Columbia University, Ctr for Neurobiol & Behav, NYC NY (2007)

Columbia University, Retreat PhD Program Ctr for Neurobiol & Behav, (2007)

University of Kentucky, College of Pharmacy, Lexington, KY (2007)

Regeneron, Tarrytown, NY (2006)

Acumen Pharmaceuticals, San Francisco (2006)

University of Manitoba, Dept of Pharmacol. and Ther, Winnipeg, Canada (2006)

Columbia University, Serjevski Center, NYC, NY (2006)

Nathan Kline Institute, Dementia Res. Program, Orangeburg, NY (2006)

University of Fukuoka, Dept of Physiology, Japan (2005)

Mitsubishi Pharma Corp, Yokohama, Japan (2005)

Univeristy of Ragusa, Italy (2005)

Roche, Palo Alto, CA (2005)

Merck, Cambridge, UK (2004)

University of Catania, Dept of Physiology, Italy (2004)

Istituto Superiore di Sanità, Rome, Italy (2004)

Columbia University, Taub Institute, NYC, NY (2003)

University of Pennsylvania, Ctr for Neurodeg. Dis. Res., Phyladelphia, PA (2003).

Wyeth, Princeton (2002)

Columbia University, Taub Institute, NYC, NY (2002).

Helicon Therap., Cold Spring Harbor, NY (2002).

SUNY, Dept Anatomy & Cell Biology, New York, NY (2000).

University of Pisa, Institute of Psychiatry, Italy (1999).

Rutgers University, Dept Neurosci. & Cell Biol. (1998).

5

SUNY, Dept Anatomy & Cell Biology, New York, NY (1998).

Mt. Sinai School of Med., Neurobiol. of Aging Lab., New York, NY (1998).

Nathan Kline Institute, Dementia Res. Program, Orangeburg, NY (1997).

University of South Alabama, Dept of Struct. and Cell Biol , Mobile, AL (1997).

Columbia University, Dept Psychiatry, NYC, NY (1997).

Yeshiva University (A Einstein Col Med), Dept Neurosc, New York, NY (1997).

Allegheny University, Neurobiology and Anatomy Dept, Philadelphia, PA (1996).

University of Bologna, Institute of Physiology, Italy (1995).

University of Torino, Dept of Physiology & Anatomy, Italy (1994).

University of Verona, Institute of Physiology, Italy (1994).

University of Milano, Institute of Pharmacological Sciences, Italy (1993).

University of Modena, Institute of Physiology, Italy (1993).

University of Bologna, Institute of Physiology, Italy (1993).

University of Torino, Dept of Physiology & Anatomy, Italy (1992).

University of Ferrara, Institute of Physiology, Italy (1992).

University of Pisa, Institute of Physiology, Italy (1992).

University of Catania, Institute of Physiology, Italy (1992).

University of Bern, Institute of Physiology, Switzereland (1992).

Rhone-Poulenc Rorer, Electrophysiol Dept, France (1992).

SISSA, Biophys Lab, Italy (1992).

University of Perugia, Institute of Physiology, Italy (1991).

University of Zurich, Brain Research Institute, Switzereland (1991).

Pharmacia,CNS Dept, Milan Italy (1991).

SUNY, Dept of Pharmachology, New York, NY (1990).

Georgetown University, Fidia Research Foundation, Washignton DC (1989).

6th CapoBoi Conference on Neuroscience, Cagliari, Italy (1989).

Other 1995 Chairperson, Society for Neuroscience, Washington, D.C., U.S.A. 2008 Chairperson, ICAD 2008, Chicago, IL, USA 2008 Chairperson, New York Academy of Science, The 5th Allym-NYP-

Columbia-Weill Cornell Symposium, NYC, USA 2010 Chairperson, Society for Neuroscience, Washington, D.C., U.S.A. 2011 Organizer Symposium on Epigentics of Alzheimer’s disease at NYAS, NYC, NY

USA 2010-2011 Featured on "bigthink.com". 2012 Chairperson, Society for Neuroscience, Washington, D.C., U.S.A. Professional Organizations, Societies and Service

Society for Neuroscience (USA)

I.B.R.O.

Italian Society for EEG and Clinical Neurophysiology

Italian Society for Neuroscience

Italian Society for Physiology

Major Committee Assignments:

6

1995-2000 New Zealand Neurological Foundation, Scientific Advisory Board

(reviewed grant applications in the field of Neuroscience from Academic

Institutions in New Zealand)

2000 - Present Italian Ministry of University, National Scientific Committee for Grant Evaluation

(reviewed research projects as an external member of a national panel.

Applications are in the field of Neuroscience and are submitted from Academic

Institutions in Italy)

2001 - Present Alzheimer’s Association (reviewed international applications submitted to their

annual research grants program)

2000 - Present Institute for the Study of Aging / Alzheimer’s Drug Discovery Foundation

(member of their Scientific Review Board. Periodically reviewed international

grant applications from Academia and Industry. Focus on drug discovery in aging

and Alzheimer’s Disease)

2002 Philip Morris (reviewed grant applications in the field of neuroscience)

2002 “Ad hoc” expert EFSA GMO panel (to advise European Food Safety

Authority which is responsible for evaluating the safety of all genetically modified

foods).

2003 - Present NIH: served on the following drug discovery review groups (ZRG1 MDCN-

C/MNPS-C, ZRG1 GGG-T), as well as review groups for P01s, and special

emphasis panels

2004 - Present Wellcome Trust (reviewed grant applications. The Wellcome Trust is the largest

charity in the UK funding innovative biomedical research, in the UK and

internationally)

2004-2008 Human Frontier Science Program (reviewed grant applications for Post-

Doctoral fellowships. The organization supports novel, innovative and

interdisciplinary basic research focused on the complex mechanisms of living

organisms. A clear emphasis is placed on novel collaborations that bring

biologists together with scientists from fields such as physics, mathematics,

chemistry, computer science and engineering to focus on problems at the frontier

of the life sciences).

2006 - Present Science Foundation Ireland (reviewed for the Principal Investigator Programme

Grant. The foundation was created by the Irish Government to invest significant

funds in leading researchers working in fields of science and enginnering)

2007 - Present Medical Research Council (MRC) (reviewed grant applications for the New

Investigator Awards. The MRC is funded by the UK Government and supports

medical research in the UK)

2008 - Present National Medical Research Council (NMRC) (evaluated applications for

Individual Research Grant. The NMRC is funded by the Government of Singapore

and supports medical research in Singapore)

2008 - Present Alzheimer’s Society – UK (reviewed applications submitted to their annual

research grants program)

2008 - 2012 Department of Veteran Affairs (served on the following review group:

Neurobiology D)

2011 - Present Ministero della Salute (Italy) (evaluated applications for Individual Research

Grant, Program Projects and Industry/Academia collaborations)

7

2011 European Research council (evaluated applications for Individual Research Grant)

2012 - Present Research Grant Council (RGC) of Hong Kong (evaluated applications for

Individual Research Grant)

2012 Czech Scienze foundation (evaluated applications for Individual Research Grant)

2013 NSF (evaluated applications for Individual Research Grant)

2013 - Present The French National Research Agency (ANR) (evaluated applications for

Individual Research Grant)

2013 - Present The Netherlands Organisation for Health Research and Development (evaluated

applications for Individual Research Grant)

2013 - Present The W. Garfield Weston Foundation (evaluated applications for Individual

Research Grant)

2014-2017 Society for Neuroscience Program Committee

Journal reviews: Cell, Neuron, J. Neurosci., JCI, Proc. Natl. Acad. Sci. U S A, Nature

Communications, J. Neurophysiol., J. Neurobiol., JBC, Neurobiol. Dis., Neurobiol. Aging, J.

Cell Sci., Neuroreport, Neurosci. Lett., Cellular & Molecular Biology Letters, Current Opinion in

Molecular Therapeutics, Molecular Psychiatry, Expert Opinion in Drug Discovery, The Scientic

World, ChemComm, Mol. Neurodegeneration, JAD, Neuroscience, J. Neurochem, Brain,

Neuropharmacology, JPET, PlosOne, Frontiers in Neuroscience.

From 2015: Editorial Board Scientific Reports

From 2008: Associate Editor J. Neuroscience (section on Development/Plasticity/Repair);

From 2010: Associate Editor JAD and Frontiers in Alzheimer's Disease;

From 2011: Associate Editor PlosOne.

Departmental and University Committees

2012 – Present Member, The Neurobiology and Behavior Graduate Program Internal

Advisory Committee

2012 – Present ad hoc Member, Departmental Tenured Committee Meetings

Fellowship and Grant Support

Past Support

1R01NS40045 (Principal Investigator) 8/1/01-7/31/05

NIH Direct costs: $700,000

Title: The Role of Presynaptive Protein in Transmitter Release

The major goal of this project is to gain a better understanding of the mechanisms underlying

neurotransmitter release.

P01-AG17490 (Principal Investigator Proj. 3 and Behav. Core) 9/01/00-08/31/11

NIH/NIA Direct costs: $1,176,387

Cellular Cofactors, Neuronal Stress and Rescue, Aging and AD

Project Title: ABAD AND Aß-induced cell stress and synaptic dysfunction

This project examines the role of RAGE and ABAD interaction with amyloid-ß peptide in the

pathogenesis of Aß-induced cell stress.

8

R01 NS-1507623 (Co-Investigator) 07/01/03-06/30/08

NIH Direct costs: $ 349,152

Title: Pathology and Biology of Neurodegenerative Diseases

The major goal of this project is to determine how and whether cAMP/PKA/CREB pathway

is involved in amyloid-beta impairment of synaptic transmission.

R01 NS-049442 (Principal In vestigator) 03/15/05-03/14/10

NIH/NINDS Direct costs: $1,359,498

Title: Mechanisms of synaptic dysfunction by Amyloid-beta peptides

The major goal of this project is to identify the target of amyloid-beta during impairment of

synaptic function in basal conditions and during synaptic plasticity.

R21 AG027468 (Principal Investigator) 04/01/07-03/31/09

NIH/NIA Direct costs: $275,000

Title: NO/cGMP/CREB pathway enhancers for treatment of Alzheimer's disease

The major goal of this project is identify novel molecules enhancing activation of cGMP-

dependent protein kinases as possible therapeutic tools against Alzheimer’s disease.

U01-AG028713 (Principal Investigator) 03/1/08-06/30/12

NIH/NIA Direct costs: $ 1,897,383

Title: Calpain Inhibitors against Alzheimer's Disease

The major goal of this project is to develop new calpain inhibitors that might be beneficial

against synaptic dysfunction and memory loss in Alzheimer’s disease.

U01-AG031294 (Co-Investigator) 09/15/08-06/30/11

NIH/NIA Direct costs: $319,028

Title: Harnessing GABA and NO mimetic activity for Alzheimer's therapy

The major goal of this application if to develop new nitric oxide donors that might be beneficial

against synaptic dysfunction and memory loss due to amyloid- elevation

U01-AG032973 (Principal Investigator) 03/01/11-02/28/14

NIH/NIA Direct costs: $821,729

Title: Novel PDE5 inhibitors as a therapeutic tool against Alzheimer's Disease

The goals of this project are to find phosphodiesterase 5 inhibitors that might be used in chronic

CNS diseases such as Alzheimer's disease.

Not Available (Principal Investigator) 12/31/10-12/30/13

Thome Memorial Foundation Direct costs: $750,000

Title: Histone Acetyltransferase (HAT) Activators as Chromatin Remodelers for the

Treatment of Memory Loss.

The goal of this project is to design and synthesize HAT activators that are optimized for AD.

N/A (Principal Investigator) 12/01/03-11/30/06

Alzheimer’s Association Direct costs: $239,974

9

Title: Neuronal RAGE and Amyloid-beta peptide-induced perturbation of synaptic

plasticity

The major goal of this project is to determine how and whether neurotransmission, the

impairment of which is a neuropathologic hallmark of AD, is altered by RAGE interaction with

A .

Alzheimer’s Association (Principal Investigator) 08/01/09-07/30/12

Alzheimer’s Association Direct costs: $240,000

Title: Dysregulation of histone acetylation in Alzheimer Disease

The goal of this application is do define whether histone acetylation is modified following

elevation of beta-amyloid.

Not Available (Principal Investigator) 07/01/07-06/30/09

Alzheimer’s Association Direct costs: $250,000

Title: CBP involvement in Alzheimer’s disease and its potential therapeutic value

The goal of this project is to determine whether long-lasting changes at the level of chromatin

occur during increase of beta-Amyloid.

Not Available (Co-Investigator) 04/01/07-03/31/09

AHAF Direct costs: $500,000

Title: New anti-aggregating drugs against Alzheimer disease

The major goal of this project is to develop new compounds that interfere with oligomerization

of amyloid-

N/A (Principal Investigator) 08/01/00-03/30/05

The Institute for the Study of Aging Direct costs: $209,512

Title: Calpain Inhibitors: A Treatment of Alzheimer’s Disease

The major goals of this project are to test whether calpain inhibitors can be used to rescue

changes of synaptic transmission in hippocampal cell culture.

2001-05086-REN-RES (Principal Investigator) 10/01/97-Ren. 07/01/01-6/30/04

Whitehall Foundation, Inc. Direct costs: $300,000

Title: The biology of learning and memory: presynaptic mechanisms of synaptic plasticity

in cultured hippocampal neurons.

The major goal of this project is to gain a better understanding of the release mechanisms

underlying synaptic plasticity.

N/A (Principal Investigator) 7/01/01-6/31/04

Speaker’s Fund for Biomedical Research Direct costs: $276,000

Title: ABAD and Amyloid-beta Peptide-induced Synaptic Impairment

The major goal of this project is to determine how and whether neurotransmission, the

impairment of which is a neuropathologic hallmark of AD, is altered by ABAD interaction with

Aβ.

R01-MH067229 (Co-Investigator) 03/15/09-03/14/15

10

NIH/NIMH Direct costs: $125,000

Title: Role of cGKII in AMPA Receptor Transport

The goal of this application is to determine the role of cGKII in regulation of AMPA receptor

trafficking.

Not Available (Principal Investigator) 12/01/12-11/30/14

Dept. of Defense Direct costs: $500,000

Title: The role of PP2A methylation in susceptibility and resistance to TBI and AD-

induced neurodegeneration

The overall scope of this project is to check the hypothesis that sensitivity to both traumatic brain

injury and AD-related impairments is impacted by PP2A methylation and PP2A-dependent

changes in tau phosphorylation

NFL Charities (Principal Investigator) 09/01/12-09/28/14

NFL Charities Direct costs: $100,000

Title: The role of PP2A methylation in chronic traumatic encephalopathy susceptibility

and recovery.

The goal of this project is to asses the effect of PP2A methylation on the response to brain

injury using an open skull methodology.

R01-AG034248 (Principal Investigator) 07/01/10-06/30/15

NIH/NIA Direct costs: $ 1,416,889

Title: Endogenous amyloid-beta in synaptic function and memory

The goal of this application is to study the physiologic function of amyloid-beta

Department of Defense (Principal Investigator) 06/01/14-5/31/15

DoD: DURIP Program (Principal Investigator)

Title: SECTOR® Imager apparatus for research to identify biomarkers of severity and

susceptibility to TBI-associated cognitive and behavioral impairments.

The purpose of this equipment grant is to purchase the SECTOR® Imager 2400A to support

brain injury activities.

Present Support

R01-NS049442 (Principal Investigator) 07/01/05-06/30/16

NIH/NINDS Direct costs: $1,789,070

Title: SUMOylation and Amyloid-beta Elevation

The goal of this project is to determine the involvement of SUMOylation in Aβ induced

synaptic and memory dysfunctions.

U01-AG043415 (Co-Investigator) 09/30/12-09/29/17

NIH/NIA Direct costs: $477,732

Title: Preclinical Alzheimer’s disease drug development of novel MAPK inhibitor

The goal of this project is to perform preclinical development studies necessary for

obtaining an Investigational New Drug (IND) approval for a New Molecular Entity (NME) as

defined by FDA.

11

R01 NS074536 (Co-Investigator) 01/01/11-12/31/15

NIH/NINDS Direct costs: $218,750

Title: Validating a Novel Lipid Phosphatase Target in Alzheimer’s Disease

This grant is to investigate the role for synaptojanin 1 in Alzheimer’s disease.

R01 NS056049 (Co-Investigator) 07/01/12-06/30/17

NIH/NINDS Direct costs: $125,000

Title: Role of phosphoinositides in neuronal membrane traffic and neurodegeneration

The goal of this grant is to characterize the role of PIP3 in the trafficking and processing

of APP as well as in neuronal autophagy and the clearance of tau aggregates.

Christopher L. Moseley Foundation (Principal Investigator) 12/01/13-11/30/15

Christopher L. Moseley Foundation Direct costs: $50,000

Title: Synaptic Dysfunction in an iPSC model of Alzheimer s Disease

The goal of this grant is to develop neurons from fibroblasts derived from Alzheimer’s

patients displaying changes in synaptic function, using stem cell technology.

R01NS092045 (Principal Investigator) 04/01/15-3/31/20

NIH/NINDS Direct costs: $1,250,000

Title: The regulation of beta-amyloid sensitivity and Alzheimer's related impairments

by PP2A

The goal of this project is to examine the ability of the serine/threonine protein

phosphatase, PP2A, to control sensitivity to the pathological actions of beta-amyloid through the

APP intracellular domain.

AZ140095 (Principal Investigator) 09/01/15-8/31/18

Department of Defense Direct costs: $500,000

Title: TBI induced formation of toxic tau and its biochemical similarities to tau in AD

brains.

The overall scope of this project is determine the molecular mechanisms by which the

Alzheimer protein tau contributes to cognitive impairments associated with traumatic brain

injury and Alzheimer’s disease.

R01AG049402 (Principal Investigator) 09/01/15-03/31/20

NIH/NIA Direct costs: $1,250,000

Title: Extracellular tau oligomers and Alzheimer disease

The overall goal of this application is to determine whether tau oligomers impair synaptic

function and memory.

Pending Support

Not Available (Principal Investigator) 01/01/16 - 12/31/17

Harrington Discovery Institute

Title: Drug development of a novel PDE5 inhibitor against Alzheimer’s disease

12

The goal of this application is to develop PDE5 inhibitors that are tailored to treat a CNS

disease like Alzheimer’s disease.

Not Available (Principal Investigator) 01/01/16 - 12/31/17

Thome Award

Title: Drug development of a novel PDE5 inhibitor against Alzheimer’s disease

The goal of this application is to develop PDE5 inhibitors that are tailored to treat a CNS

disease like Alzheimer’s disease.

Teaching Experience and Responsabilities

Specific Courses 1995 – 1998 Instructor of Neuroanatomy, Columbia University 1998 - 2000 Lectures and organized laboratory in Neuroanatomy, SUNY/Downstate 2005 - 2006 Directed the Pathology student Journal clubs 2007 - 2008 Directed the Pathology student Journal clubs 2007 - 2010 Journal clubs for the students of the Program in Neurobiology and Behavior 2008 - 2009 Lecturing at the Neural Science course for first year medical students, Columbia

University. 2008 - Present Lecturing at the "Mechanisms of Human Disease" course, Columbia University.

Ph.D./Master’s Theses Trainees

Jan Orozco (Integrated Program, started in September 2006 immediately after his rotation in the

lab, successfully defended his thesis in 2011);

Linda (Bobbi) Lee (Program in Neurobiology and Behavior, started in January 2008 immediately

after her rotation in the lab, successfully defened her thesis in 2013).

Ph.D. Examination-, Advisory -, and Defense Committees

Mentor for the following training programs: Integrated Program in Cellular Molecular and

Biomedical Studies, Pathobiology and Molecular Medicine Program, MD/PhD Program, the

Program in Neurobiology and Behavior

Qualifying exams: Hwang Jeremy (MD/PhD Program, October 2005), Mohsin S Ahmed

(Neurobiology & Behavior Program and MD/PhD Program, November 2006), Gina-Marie Finan

(Integrated Program, January 2007), Eileen Guilfoyle (Integrated Program, January 2007), Punita

Bhansali (Integrated Program, December 2007), Roger Lefort (Integrated Program, February

2008), Cyndel Vollmer (Integrated Program, Fall 2013).

Thesis Committee: Nicole Lewandowski (Integrated Program, March 2007), Sidonie Jones

(Integrated Program, March 2007), Kelley Remole (Program in Neurobiology and Behavior,

September 2008), Maria Avrutsky (Integrated Program, March 2011), Franklin Garcia (Integrated

Program, March 2011).

Defense Thesis: Yafell Serulle (External Member for PhD Program NYU, September 2007),

Deirdre DeSteno (Program in Pharmacology, December 2007), Anthony DeCostanzo, (Program

13

in Pharmacology, December 2007), Roger Lefort (Integrated Program, February 2011), Kelley

Remole (Program in Neurobiology and Behavior, March 2011).

Other Trainee Advisory Roles, e.g. postdoctoral trainees, visiting scientists, student trainees

Post-doctoral trainees: Anne Cecile Trillat, Ipe Ninan, Fortunato Battaglia, Bing Gong, Daniela

Puzzo, Fabrizio Trinchese, Mauro Fa’, Itsik Francis, Valentina Echeverria, Elena Leznik, Mikako

Sakurai, Yan Feng, Jole Fiorito, Andy Teich, Russsell Nicholls, Deborah Pre’, Peter

Koppensteiner, Faisal Saeed, Rosita Purgatorio, Jordano Brito Moreira,

Rotating students: Jan Orozco (Integrated Program, Summer 2006), David Malito (Neurobiology

& Behavior Program, Summer 2006), Pei-Ken Hsu (Integrated Program, Spring 2006), Linda

(Bobbi) Lee and Irene H. Ballagh (Program in Neurobiology and Behavior, Fall 2007), Nsikan

Akpan (Pathology, Fall 2007), Yige Guo (Pathology, Fall 2008), Kelvin Pau (Pathobiology, Fall

2009), Shwan Nelson Jordan (Pathobiology, Fall 2009), Preeti Putcha (Pathobiology, Winter

2009), Frankyin Garcia (Pathobiology, Fall 2010), John Kerk (Neurobiology & Behavior

Program, Winter 2011), Rebecca Williamson (MD, PhD Program, Summer 2011), Cyndel

Vollmer (Integrated Program, Fall 2012), Tiara Ahmad (Pathology Program, Fall 2013),

Francesca Garretti (Pathobiology and Molecular Medicine program, Fall 2014), Veronica

Birdsall (Neurobiology & Behavior Program, Winter 2015), Qi Jin Pathobiology and Molecular

Medicine Program, Winter 2015), Emma Grosserod (Pharmacology and Molecular Signaling

Program, Winter 2015).

Residents: Jenny Libien (Pathology, between 2005-2006), Andy F. Teich (Pathology, from 2009-

2013)

Fellowships awarded to students: Jan Orozco (NIH/NIMH: Understanding the neuronal function

of dysbindin); Linda (Bobbi) Lee (NIH/NIA: Astrocytes and physiological amyloid-beta

signaling).

Summer Undergraduate Students: Karina Lam (Harvard Undergraduate Program, 2005);

Francesco Michelassi (Columbia Undergraduate Program, 2008-2010); Varhade, Suchita

Pradnya (Barnard College, 2008-2010), Joshua Jay (Yeshiva University, 2008), Sudha Rao

(Barnard College, 2011-2013), Ben Gong (Columbia Undergraduate Program, 2010-2012).

Others: Interviews of many candidates for the Integrated Program in Cellular Molecular and

Biophysical Studies, the Pathology and Cell Biology Program, the MD/PhD Program.

Itsik Francis (University College London, UK), Lucy Privitera (University of Catania, Italy), and

Vorapin Chinchalongporn (Mahidol University, Thailand) have joined my laboratory since

September 2006 to complete their work in view of their PhD thesis in their countries.

Description of teaching and training activities prior to joining Columbia University.

Lectures and organized laboratories at the Anatomy course for medical students at SUNY-HSCB

(New York City) during the years 1999 and 2000.

Rotating Students: Jie Ma (Neural & Behavioral Science Program, fall 1999)

Summer Undergraduate Students: Joel Jacob (Combined undergraduate/MD Program between

USA and Foreign Countries), John Ross-Rizzo (NYU Undergraduate Program, 2002 and 2003),

Sarah Khan (Combined undergraduate/MD Program between USA and Foreign Countries).

14

Others: Daniela Puzzo (University of Catania, Italy) joined my laboratory in 2002-2003 to

complete her work in view of defending her PhD thesis in her country.

Former Lab Members Holding Academic Positions: Ipe Ninan (Tenure Track Assistant Professor

Dept of Psychiatry, NYU School of Medicine); Fortunato Battaglia (Tenured Associate Professor

of Neuroscience and Clinical Neurology, Seton Hall University); Andy F. Teich (Tenure Track

Assistant Professor Dept of Pathology & Cell Biology, Columbia University); Daniela Puzzo

(Tenured, Associate Professor Dept of Physiology, University of Catania, Catania, Italy), Russell

Nicholls (Assistant Professor Dept of Pathology & Cell Biology, Columbia University).

Patents

a) Methods and Compositions for Enhancing Memory. The invention is directed to methods for

enhancing memory by administering low doses of beta amyloid peptide. The invention also

encompasses methods for increasing synaptic plasticity in a subject which comprises

administering to the subject low doses of beta amyloid peptide.

Filed on 03/30/09, Patent application number: 12/414160

Inventors: Arancio, O., Puzzo, D., Alberini, C., Mathews, P

b) Histone acetyltransferase activators and uses thereof. The researchers synthesized a new class

of small molecule HAT activators with greater solubility and membrane permeability. The HAT

activators work by promoting histone acetylation, as opposed to current therapies aimed at

preventing deacetylation with HDAC inhibitors. In vivo studies showed that the compound not

only crossed the blood-brain barrier, but also increased histone acetylation levels in the

hippocampus and ameliorated memory deficits in a mouse model of Alzheimer's disease.

Filed on 12/10/10, Patent application number: PCT/US2010/059925

Inventors: Arancio, O., Francis Y, Fa' M., Feng Y, Landry, DW, Deng, SX

c) Histone acetyltransferase modulators and uses thereof. The researchers synthesized new small

molecules that differentially increase or decrease the HATs, CBP and P300.

Filed on 12/22/11, Patent application number: PCT/US2011/066851

Inventors: Arancio, O., Francis Y, Fa' M., Feng Y, Landry, DW, Fiorito J., Luzac M., Deng, SX

d) Uses of Histone Acetyltransferase activators. The researchers have demonstrated that small

molecule HAT activators can be beneficial for cancer treatment.

Filed on 06/11/12, Patent application number: PCT/US2012/041907

Inventors: Arancio, O., Francis Y.

e) Phosphodiesterase inhibitors and uses thereof. The researcher have synthesized a new class of

small molecule PDE5 inhibitors for therapeutic use in Alzheimer’s Disease.

Filed on 09/29/09, Patent application number: PCT/US2009/058813

Inventors: Arancio, O., Landry, DW, Feng, Y., Deng, SX

f) Phosphodiesterase inhibitors and uses thereof. The invention provides novel

benzonaphthyridine derivatives that inhibit PDE5 for therapeutic use in Alzheimer’s Disease.

15

Filed on 01/17/13, Patent application number: PCT/US2013/021918

Inventors: Arancio, O., Landry, DW, Fiorito, J., Deng, SX, Wasmuth, A.

g) Novel Phosphodiesterase inhibitors and uses thereof. The invention provides novel

benzonaphthyridine derivatives that inhibit PDE5 for therapeutic use in Alzheimer’s Disease.

Provisional 0019240.00963US3

Inventors: Arancio, O., Landry, DW, Fiorito, J., Deng, SX, Wasmuth, A.

h) Increasing learning and memory in amyloid-β related neurodegenerative disorders such as

Alzheimer's. The invention is directed to methods for increasing learning and memory in a

subject with a neuropathological condition, specifically a condition related to elevated beta-

amyloid deposition, the method comprising administering to the subject an effective amount of a

compound capable of increasing the activity of Uch-L1. The invention is also directed to

screening methods for identifying compounds that enhance

the activity of the proteasome system, Uch-L1, or both.

Filing date: Jun 29, 2006 Issued patent: US7947279 (Issue date May 24, 2011)

Inventors: Arancio, O. Shelanski, M.L., Gong, B.

i) New compounds having a selective PDE4D inhibiting activity. The invention is directed

towards the synthesis of a new class of phosphodiesterase 4D inhibitors for the therapy of

Alzheimer’s disease

Filing date: 14/02/14. Patent application number: 14425015.6

Inventors: Arancio, O., Fa’, M., Prickaerts, J., Bruno, O., Fossa, P., Fedele, E., Ricciarelli, R.

l) Novel cysteine protease inhibitors and uses thereof. The invention is directed towards the

synthesis of a new class of calpain inhibitors for the therapy of Alzheimer’s disease

Filing date: 02/01/13. Patent application number: PCT/US2013/024364

Inventors: Arancio, O., Fa’, M., Schiefer, I.T., Thatcher, G.R.

m) MAP Kinase modulators and uses thereof. The invention is directed towards the synthesis of

a new class of p38alpah MAP kinase inhibitors against neurodegeneration,

Filing date: 03/17/14. Patent application number: PCT/US2014/030260

Inventors: Arancio, O., Watterson, D.M., Pelletier, J.C., Roy, S.M.

Companies

2013- Founder Appia Pharmaceutical. This is a biotechnology start-up company based on the

HAT technology

Publications A) Original Peer Reviewed Articles 1. Arancio, O., Cangiano, A., and Magherini, P. Ruolo dell'NGF nello sviluppo dei neuroni

sensitivi primari nel ratto. Boll. Soc. It. Biol. Sper. 1982; 58: 60-65.

16

2. Arancio, O., Bongiovanni, L., and De Grandis, D. Acute peroneal compartmental syndrome: report of a case. Eur.Neurol. 1985; 24:69-72.

3. Polo, A., Arancio, O., Bronzato, P., Serra, G., and De Grandis, D. Effect of aging on the

visual evoked oscillatory potentials in man. Riv. Ital. EEG Neurofisiol. Clin. 1986; 9: 29-44.

4. De Grandis, D., Arancio, O., and Serra, G. An electroneurographic response. Muscle &

Nerve 1986; 9: 185. 5. Provenzano, C., Arancio, O., Evoli, A., Rocca, B., Bartoccioni, E., De Grandis, D., and

Tonali, P. Familial autoimmune myasthenia gravis with different pathogenetic antibodies. J. Neurol. Neurosurg. & Psych. 1988; 51: 1228-1230.

6. Arancio, O., Bongiovanni, LG., Bonadonna, G., Tomelleri, G., and De Grandis, D.

Congenital muscular dystrophy and cerebellar vermis agenesis in two brothers. Ital. J. Neurol. Sci. 1988; 9: 485-489.

7. Arancio, O., Cangiano, A., Magherini, PC., and Pasino, E. Effects of reinnervation with

normal and tetrodotoxin-inactive nerves on resting membrane potential of rat skeletal muscle. Neurosci. Lett. 1988; 88: 179-183.

8. Arancio, O., Cangiano, A., and De Grandis, D. Fibrillatory activity and other membrane

changes in partially denervated muscles. Muscle & Nerve 1989; 12: 149-153. 9. Arancio, O., Bonadonna, G., Calvani, M, Giovene, P., Tomelleri, G., and De Grandis, D.

Transitory L-carnitine depletion in rat skeletal muscle by D-carnitine. Pharmacol. Res. Comm. 1989; 21: 163-168.

10. Yoshimura, M., Murase, K., Arancio, O., and MacDermott, AB. Glutamate receptor

agonists-induced inward currents in spinal dorsal horn neurons dissociated from the adult rat. Neurosci. Res. 1991; 12: 528-535.

11. O'Dell, T.J., Hawkins, R.D., Kandel, E.R., Arancio, O. Tests of the roles of two

diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc. Natl. Acad. Sci. U S A, 1991; 88: 11285-11289.

12. Tiedge, H., Fremeau, R.T.Jr., Weinstock, P.H., Arancio, O., and Brosius, J. Dendritic

location of neural BC1 RNA. Proc. Natl. Acad. Sci. U S A, 1991; 88: 2093-2097.

13. Arancio, O., and MacDermott, AB. Differential distribution of excitatory amino acid

receptors on embryonic rat spinal cord neurons in culture. J. Neurophysiol. 1991; 65: 899-913.

14. Arancio, O., Buffelli, M., Cangiano, A., Pasino, E. Nerve stump effects in muscle are

independent of synaptic connections and are temporally correlated with nerve

degeneration phenomena. Neurosci. Lett. 1992; 146: 1-4.

17

15. Arancio, O., Yoshimura, M., Murase, K., MacDermott, AB. The distribution of

excitatory amino acid receptors on acutely dissociated dorsal horn neurons from postnatal

rats. Neuroscience 1993; 52: 159-167.

16. Arancio, O., Gulyas, A., Freund, T., Korn, H., Miles, R. Evidence that excitatory

synaptic connections onto hippocampal inhibitory cells may involve a single transmitter release site. J. Physiol. 1994; 481: 395-405.

17. Hawkins, R.D., Zhuo, M., Arancio, O. Nitric oxide and carbon monoxide as possible

retrograde messengers in hippocampal long-term potentiation. J. Neurobiol. 1994;

25:652-665.

18. Arancio, O., Kandel, E.R., Hawkins, R.D. Activity-dependent long-term enhancement of

transmitter release by presynaptic 3',5'-cyclic GMP in cultured hippocampal neurons.

Nature, 1995; 376:74-80. PMID: 7596438. 19. Arancio, O., Lev-Ram, V., Tsien, R.Y., Kandel, E.R., Hawkins, R.D. Nitric oxide acts as

a retrograde messenger during long-term potentiation in cultured hippocampal neurons. J. Physiol (Paris), 1996; 90: 321-322.

20. Pasino, E., Buffelli, M., Arancio, O., Busetto, G., Salviati, A., Cangiano,A. Effects of

long-term conduction block on membrane properties of reinnervated and normally innervated rat skeletal muscle. J. Physiol. 1996; 497: 457-472.

21. Lopez-Garcia, J.C., Arancio, O., Kandel, E.R, Baranes, D. A presynaptic locus for long-

term potentiation of elementary synaptic transmission at mossy fiber synapses in culture.

Proc. Natl. Acad. Sci. U S A, 1996; 93: 4712-4717.

22. Arancio, O., Kiebler, M., Lee, C.J., Lev-Ram, V., Tsien, R.Y., Kandel, E.R., Hawkins,

R.D. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell, 1996; 87: 1025-1035. PMID: 8978607.

23. Son, H., Lu, Y-F., Zhuo, M., Arancio, O., Kandel, E.R., Hawkins, R.D. The specific role

of cGMP in hippocampal LTP. Learn. & Mem. 1998; 5: 231-245. PMID: 10454367

24. Arancio, O., Antonova, I., Gambaryan, S., Lohmann, S.M., Wood, J., Lawrence, D.,

Hawkins, R.D. Presynaptic cGMP-dependent protein kinase contributes to long-lasting

potentiation in cultured hippocampal neurons. J. Neurosci. 2001; 21: 143-149. PMID:

11150330.

25. Antonova, I., Arancio, O., Trillat, A-C., Zablow, L., Kandel, E.R., Hawkins, R.D. Rapid

increase in immunoreactive presynaptic terminals during long-lasting potentiation.

Science. 2001; 294: 1547-1550.

*26. Di Rosa, G., Odrljin, T., Nixon, RA, *Arancio, O. Calpain inhibitors: a treatment for

Alzheimer’s disease. J. Mol. Neurosci., 2002; 19: 135-141.

18

27. #Vitolo, O.V., #Sant’Angelo A., Costanzo, V., Battaglia, F., #Arancio, O., # Shelanski, M.

Amyloid peptide inhibition of the PKA/CREB pathway and long-term potentiation:

reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U S A, 2002; 99: 13217-13221.

*28. #Battaglia, F., #Trinchese, F., Liu, S., Walter, S., Nixon, RA, *Arancio, O. Calpain

Inhibitors, a Treatment for Alzheimer’s Disease: Position Paper. J. Mol. Neurosci., 2003;

20: 357-362.

29. Petrone, A., Battaglia, F., Wang, C., Dusa, A., Su, J., Zagzag, D., Bianchi, R., Casaccia-

Bonnefil, P., Arancio, O., Sap, J. Receptor protein tyrosine phosphatase alpha (RPTP )

is essential for hippocampal neuronal migration, long-term potentiation, and working

memory. EMBO J., 2003; 22: 4121-31.

30. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N.,

Duman, R., Lee, J., Arancio, O., Belzung, C., and Hen, R. Hippocampal Neurogenesis

contributes to the behavioral effects of antidepressants. Science, 2003; 301: 805-9.

Faculty of 1000 Top 10 Neuroscience.

*31. Trinchese, F., Liu, S., Ninan, I., Puzzo, D., Jacob, J.P., *Arancio, O. Cell cultures from

animal models of Alzheimer’s disease as a tool for a faster screening and testing of drug

efficacy. J. Mol. Neurosci., 2004; 24: 15-22.

*32. Ninan, I., *Arancio, O. Presynaptic CaMKII is necessary for synaptic plasticity in

cultured hippocampal neurons. Neuron, 2004; 42: 129-141. Faculty of 1000 Top 10

Neuroscience. http://invention.swmed.edu/frisc/faculty/sudhof/profile_this_year.shtml.

33. Lustbader, J. W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C.,

Chen, X., Pollak, S., Chaney, M., Trinchese, F., Liu, S., Gunn-Moore, F., Lue, L.F.,

Walker, D.G., Kuppusamy, P., Zewier, Z.L., Arancio, O., Stern, D., Yan , S.S., Wu, H.

ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science,

2004; 304: 448-452. Faculty of 1000 Top 10 Neuroscience.

*34. Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P., *Arancio, O. Progressive

age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol.,

2004; 55: 801-814.

*35. Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kholodilov,

N., Dauer, W., Hawkins, R.D., *Arancio, O. -synuclein produces a long-lasting

increase in neurotransmitter release. EMBO J., 2004, 23: 4506-16.

36. Veeranna, Kaji, T., Boland, B., Odrljin, T., Mohan, P., Basavarajappa, B., Peterhoff, C.,

Cataldo, A., Rudnicki, A., Sheng Li, B., Amin, N., Pant, H.A., Hungund, B.L., Arancio,

O., Nixon, R.A. Calpain Mediates Calcium-Induced Activation of the Erk1,2 MAPK

19

Pathway and Cytoskeletal Phosphorylation in Neurons: Relevance to Alzheimer's

Disease. Am. J. Pathol., 2004; 165: 795-805.

37. Arancio, O., Zhang, H.P., Chen, X., Lin, C., Trinchese, F., Puzzo, D., Liu, S., Hegde, A.,

Yan, S.F., Stern, A., Luddy, J.S., Lue, L-F., Walker, D., Roher, A., Buttini, M., Mucke,

L., Li, W., Schmidt, A.M., Kindy, M., Hyslop, P., Stern, D.M., Yan S.S-D. RAGE

potentiates Aß-induced perturbation of neuronal function in transgenic mice. EMBO J.,

2004; 23: 4096-105. Faculty of 1000 Top 10 Neuroscience.

*38. Gong, B., Vitolo, O.V., Trinchese, F., Liu, S., Shelanski, M., *Arancio, O. Persistent

improvement in synaptic and cognitive functions in an Alzheimer mouse model following

rolipram treatment. J. Clin. Invest ., 2004; 114: 1624-1634. Highlighted in the "In This

Issue" section of the journal. See also http://www.alzforum.org/new/detail.asp?id=1118

39. Takuma, K., Yao, J., Huang, J., Xu, H.W., Luddy, J., Trillat, A-C, Chen, X., Stern, D.M.,

Arancio, O. Yan, S.S-D. ABAD Enhances A -induced Cell Stress via Mitochondrial

Dysfunction. FASEB J. 2005; 19: 597-8.

*40. Puzzo, D., Vitolo, O.V., Trinchese, F., Jacob, J.P., Palmeri, A., *Arancio, O. Amyloid-β-

peptide inhibits activation of the nitric oxide/cGMP/CREB pathway during hippocampal

synaptic plasticity. J. Neurosci. 2005; 25: 6887-6897.

*41. Zhang, H., Gong, B., Liu, S., Fa’, M., Ninan, I., Staniszewski, A., *Arancio, O. Synaptic

fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer’s

disease. Curr. Alzh. Res. 2005; 2: 137-140. 42. Moretti, P., Levenson, JM., Battaglia, F., Teague, R., Antalffy, B., Armstrong, D.,

Arancio, O., Sweatt, JD., Zoghbi, HY. Synaptic plasticity and learning and memory are

impaired in a mouse model of Rett syndrome. J. Neurosci. 2006 26: 319-327. (Research

Highlights Nature Rev. Neurosci. 7: 87, 2006).

43. Gong, B., Cao, Z., Zheng, P., Vitolo, O.V., Liu, S., Staniszewski, A., Moolman, D.,

Zhang, H., Shelanski, M., *Arancio, O. Ubiquitin Hydrolase Uch-L1 Rescues -

Amyloid-Induced Decreases in Synaptic Function and Contextual Memory. 2006; Cell

126: 775-788.

44. Yano, H., Ninan, I., Zhang, H., Milner, T.A., Arancio, O., Chao, M.V. BDNF-mediated

neurotransmission relies upon a myosin VI motor complex. Nat. Neurosci. 2006; 9: 1009-

18.

*45. Puzzo, D., and *Arancio, O. Fibrillar β-amyloid impairs the late phase of long-term

potentiation. Curr Alzheimer Res. 2006; 3: 179-83.

46. Ninan, I., Arancio, O. Rabinowitz, D. Estimation of the mean from sum with unknown

numbers of summands. Biometrics. 2006; 62: 918-920.

20

*47. Ninan, I., Liu, S., Rabinowitz, D., *Arancio, O. Early Presynaptic Changes during

Plasticity in Cultured Hippocampal Neurons. EMBO J. 2006; 25: 4361-4371.

*48. Liu, S., Fa', M., Ninan, I., Trinchese, F., Dauer, W., *Arancio, O. -Synuclein

Involvement in Hippocampal Synaptic Plasticity: Role of NO, cGMP, cGK, and CaMKII.

Eur. J. Neurosci. 2007; 25: 3583-96.

49. Vitolo, V., Gong, B., Cao, Z., Ishii, H., Jaracz, S., Nakanishi, K., Arancio, O., Dzyuba,

S.V., Lefort, R., Shelanski M. Protection against -amyloid induced abnormal synaptic

function and cell death by Ginkgolide J. Neurobiol. of Aging. 2009; 30: 257-65.

50. Serulle, Y., Zhang, S, Ninan I., Puzzo, D., McCarthy, M., Khatri, L., Arancio, O. and

Ziff, E.B. A novel GluR1-cGKII interaction regulates AMPA receptor trafficking.

Neuron. 2007; 56: 670-88.

*51. Echeverria, V., Berman, D.E., *Arancio, O. Oligomers of β-Amyloid Peptide Inhibit

BDNF-Induced Arc Expression in Cultured Cortical Neurons. Current Alzheimer

Research, 2007; 4: 518-521.

52. Matsuoka,Y., Jouroukhin, Y., Gray, A.J., Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu

L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-

interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in

a mouse model of Alzheimer's disease. J Pharmacol Exp Ther., 2008; 325: 146-53.

53. Berman, D.E., Dall’Armi, C., Zhang, H., Moore, A.Z., Voronov, S.V., Arancio, O., Kim,

T.W., Di Paolo, G. Oligomeric amyloid β-peptide disrupts phosphatidylinositol-4,5

bisphosphate metabolism. Nat. Neurosci. 2008; 11: 547-54.

54. Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L,

Kreber R, Honig LS, Ganetzky B, Duff K, Arancio O., Small SA. Retromer deficiency

observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and

A{beta} accumulation. Proc Natl Acad Sci U S A. 2008; 105: 7327-32.

55. Voronov SV, Frere SG, Giovedi S, Pollina EA, Borel C, Zhang H, Schmidt C, Akeson

EC, Wenk MR, Cimasoni L, Arancio O, Davisson MT, Antonarakis SE, Gardiner K, De

Camilli P, Di Paolo G. Synaptojanin 1-linked phosphoinositide dyshomeostasis and

cognitive deficits in mouse models of Down's syndrome. Proc Natl Acad Sci U S A.

2008; 105: 9415-20.

56. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M,

Figueroa H, Yu WH, Arancio O, Duff K. A transgenic rat that develops Alzheimer's

disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Neurobiol Dis. 2008; 31:46-57. PMID: 18504134.

21

*57. Trinchese, F., Fa’, M., Liu, S., Zhang, H., Hidalgo, A., Schmidt, S., Yamaguchi, H.,

Yoshii, N., Mathews, P., Nixon, R., *Arancio, O. Inhibition of calpains improves

memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin.

Invest., 2008; 118: 2796-807.

58. Du, H., Guo, L., Fang, F., Chen, D., Sosunov, S., McKhann, G., Yan, Y., Wang, C.,

Zhang, H., Molkentin, J.D., Gunn-Moore, F.J., Vonsattel, J.P., Arancio, O., Chen, J.X.,

Yan, S.S-D Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation

and ameliorates learning and memory in Alzheimer's disease. Nat. Med., 2008; 14: 1097-

105.

59. Basavarajappa BS, Ninan I, Arancio O. Acute ethanol suppresses glutamatergic

neurotransmission through endocannabinoids in hippocampal neurons. J Neurochem.

2008, 107: 1001-13.

60. Yang, T., Knowles, J.K., Lu, Q., Zhang, H., Arancio, O., Moore, L.A., Chang, T., Wang,

Q., Andreasson, K., Rajadas, J., Fuller, G.G., Xie, Y., Massa, S.M. and Longo, F.M.

Small molecule, non-peptide p75NTR ligands inhibit Aβ-induced neurodegeneration and

synaptic impairment PLoS ONE, 2008; 3: e3604.

*61 Puzzo, D., Privitera, L., Leznik, E., Fa’, M., Staniszewski, A., Palmeri, A. *Arancio, O.

Picomolar amyloid-beta positively modulates synaptic plasticity and memory in

hippocampus. J. Neurosci. 2008; 28:14537-45 (highlighted in This Week in The

Journalsection: J. Neurosci. 2008 28)

62. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, Chen JX, Schmidt AM,

Arancio O, Yan SD, Domenici L. Receptor for advanced glycation end product-

dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-

mediated cortical synaptic dysfunction. J Neurosci. 2008; 28:3521-30.

*63 Francis, I.Y., Fà, M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D.S., *Arancio,

O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's

disease. J Alzheimers Dis. 2009 18: 131-9.

64. Origlia N., Capsoni S., Cattaneo A., Fang F, Arancio O., Yan SD, Domenici L. Abeta-

Dependent Inhibition of LTP in Different Intra-Cortical Circuits of the Visual Cortex:

The Role of RAGE. J Alzheimers Dis. 2009; 17: 59-68.

*65. Puzzo, D., Staniszewski, A., Deng, S-X, Privitera, L., Leznik, E., Liu, S., Zhang, H.,

Feng., Y., Palmeri, A., Landry, D-W, *Arancio, O. Phosphodiesterase 5 inhibition

improves synaptic function, memory and Amyloid-beta load in an Alzheimer's Disease

Mouse Model. J. Neurosci. 2009; 29:8075-86. PMID:19553447

66. Gaisler-Salomon I., Miller GM, Chuhma N., Lee S., Zhang H., Ghoddoussi F.,

Lewandowski N., Fairhurst S., Wang Y., Conjard-Duplany A, Masson J., Balsam P., Hen

22

R., Arancio O., Galloway MP, Moore HM, Small SA, Rayport S. Glutaminase-Deficient

Mice Display Hippocampal Hypoactivity, Insensitivity To Pro-Psychotic Drugs And

Potentiated Latent Inhibition: Relevance To Schizophrenia. Neuropsychopharmacology.

2009; 34: 2305-22.

67. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic

spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A. 2009;

106:16877-82.

68. Arévalo JC, Wu SH, Takahashi T, Zhang H, Yu T, Yano H, Milner TA, Tessarollo L,

Ninan I, Arancio O, Chao MV. The ARMS/Kidins220 scaffold protein modulates

synaptic transmission. Mol Cell Neurosci. 2010 45:92-100. PMID: 20547223.

*69. Fa M, Orozco IJ, Francis YI, Saeed F, Gong Y, Arancio O. Preparation of oligomeric

beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices.

J Vis Exp. 2010; Jul 14;(41). pii: 1884. doi: 10.3791/1884. PMID: 20644518.

70. Origlia N, Bonadonna C, Rosellini A, Leznik E, Arancio O, Yan SS, Domenici L.

Microglial receptor for advanced glycation end product-dependent signal pathway drives

beta-amyloid-induced synaptic depression and long-term depression impairment in

entorhinal cortex. J Neurosci. 2010; 30:11414-25. PMID: 20739563.

71. Wu SH, Arevalo JC, Neubrand VE, Zhang H, Arancio O, Chao MV. The Ankyrin

Repeat-rich Membrane Spanning (ARMS)/KIDINS220 scaffold protein is regulated by

activity-dependent calpain proteolysis and modulates synaptic plasticity. J Biol Chem.

2010; Oct 13. [Epub ahead of print] PMID: 20943655.

72. Tamayev R, Giliberto L, Li W, d'Adamio C, Arancio O, Vidal R, D'Adamio L. Memory

Deficits Due to Familial British Dementia BRI2 Mutation Are Caused by Loss of BRI2

Function Rather than Amyloidosis. J Neurosci. 2010; 30:14915-14924. PMID:

21048150.

73. Tamayev, R., Matsuda, S., Fa’, M., Arancio, O., D'Adamio, L. Danish dementia mice

suggest that loss of function and not the amyloid cascade causes synaptic plasticity and

memory deficits. Proc Natl Acad Sci U S A. 2010; 107:20822-7. PMID: 2109826874.

74. Oliveira T.G., Chan R.B., Tian H., Laredo M., Shui G., Staniszewski A., Zhang H., Wang

L., Kim T.W., Duff K.E., Wenk M.R., Arancio O., Di Paolo G. Phospholipase d2

ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive

deficits. J Neurosci. 2010; 30:16419-28. PMID: 21147981.

75. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore

FJ, Xi Chen J, Arancio O, Yan SS. Inhibition of amyloid-beta (Abeta) peptide-binding

alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves

23

mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci. 2011;

31:2313-20. PMID: 21307267.

*76. Puzzo, D., Privitera, L., Fa’, M., Staniszewski, A., Hashimoto, G., Aziz, F., Sakurai, M.,

Ribe, E.M., Troy, C.M., Mercken, M., Jung, S.S., Palmeri, A., *Arancio, O. Endogenous

amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol.

2011; 69:819-30. PMID: 21472769.

77. Tamayev R, Matsuda S, Giliberto L, Arancio O, D'Adamio L. APP heterozygosity averts

memory deficit in knockin mice expressing the Danish dementia BRI2 mutant. EMBO J.

2011; 30:2501-9. PMID: 21587206.

78. Duffy AM, Schaner MJ, Wu SH, Staniszewski A, Kumar A, Arévalo JC, Arancio O,

Chao MV, Scharfman HE. A selective role for ARMS/Kidins220 scaffold protein in

spatial memory and trophic support of entorhinal and frontal cortical neurons. Exp

Neurol. 2011; 229:409-20 PMID: 21419124.

79. Tamayev R, Matsuda S, Arancio O, D'Adamio L. β- but not γ-secretase proteolysis of

APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol

Med. 2012; 4:171-9. PMID: 22170863.

80. Schiefer IT, VandeVrede L, Fa' M, Arancio O, Thatcher GR. Furoxans (1,2,5-oxadiazole-

N-oxides) as novel NO mimetic neuroprotective and procognitive agents. J Med Chem.

2012; 55:3076-87. PMID: 22429006.

81. Gaisler-Salomon I, Wang Y, Chuhma N, Zhang H, Golumbic YN, Mihali A, Arancio O,

Sibille E, Rayport S. Synaptic underpinnings of altered hippocampal function in

glutaminase-deficient mice during maturation. Hippocampus. 2012; 22:1027-39. PMID:

22431402.

82. Qin Z, Luo J, Vandevrede L, Tavassoli E, Fa' M, Teich AF, Arancio O, Thatcher GR.

Design and Synthesis of Neuroprotective Methylthiazoles and Modification as NO-

Chimeras for Neurodegenerative Therapy. J Med Chem. 2012; 55:6784-801. PMID:

2779770.

*83. Hashimoto G, Sakurai S., Teich AF, Saeed F, Aziz F, Arancio O. 5-HT4 receptor

stimulation leads to soluble APPα production through MMP-9 up-regulation. J

Alzheimers Dis. 2012; 32:437-45, PMID: 22810092.

84. Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juárez R, Horvath TL, Wardlaw SL, Plum

L, Arancio O, Accili D. FoxO1 Target Gpr17 Activates AgRP Neurons to Regulate Food

Intake. Cell. 2012; 149:1314-26. PMID: 22682251.

85. Liu X, Betzenhauser MJ, Reiken S, Meli A, Xie W, Chen BX, Arancio O, Marks AR.

Role of leaky neuronal ryanodine receptor in stress-induced cognitive dysfunction. Cell,

2012; 150:1055-67. PMID: 22939628.

24

86. Tamayev R, Akpan N, Arancio O, Troy CM, D Adamio L. Caspase-9 mediates synaptic

plasticity and memory deficits of Danish dementia knock-in mice: caspase-9 inhibition

provides therapeutic protection. Mol Neurodegener. 2012; 7:60. PMID: 23217200.

87. McIntire LB, Berman DE, Myaeng J, Staniszewski A, Arancio O, Di Paolo G, Kim TW.

Reduction of synaptojanin 1 ameliorates synaptic and behavioral impairments in a mouse

model of Alzheimer's disease. J Neurosci. 2012; 32:15271-6. PMID: 23115165.

88. Xing L, Salas M, Zhang H, Gittler J, Ludwig T, Lin CS, Murty VV, Silverman W,

Arancio O, Tycko B. Creation and characterization of BAC-transgenic mice with

physiological overexpression of epitope-tagged RCAN1 (DSCR1). Mamm Genome.

2013; 24:30-43. PMID:23096997.

89. Lombino F, Biundo F, Tamayev R, Arancio O, D'Adamio L. An Intracellular Threonine

of Amyloid-β Precursor Protein Mediates Synaptic Plasticity Deficits and Memory loss.

PLoS One. 2013; 8(2):e57120. PMID: 23451158.

*90. Teich AF, Patel M, Arancio O. A Reliable Way to Detect Endogenous Murine β-

Amyloid. PLoS One. 2013; 8(2):e55647. PMID: 23383341.

*91. Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, Francis YI, Rao S, Thakkar DM,

Deng SX, Landry DW, Arancio O. Synthesis of quinoline derivatives: Discovery of a

potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's

disease. Eur J Med Chem. 2013; 60:285-94. PMID: 23313637.

92. Knowles JK, Simmons DA, Nguyen TV, Vander Griend L, Xie Y, Zhang H, Yang T,

Pollak J, Chang T, Arancio O, Buckwalter MS, Wyss-Coray T, Massa SM, Longo FM. A

small molecule p75(NTR) ligand prevents cognitive deficits and neurite degeneration in

an Alzheimer's mouse model. Neurobiol Aging. 2013; 34: 2052-63. PMID: 23545424.

93. Pozueta J, Lefort R, Ribe EM, Troy CM, Arancio O, Shelanski M. Caspase-2 is required

for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nat Commun.

2013 4: 1939. PMID: 23748737.

94. Schiefer IT, Tapadar S, Litosh VA, Siklos M, Scism RA, Wijewickrama G, Chandrasena

RE, Sinha V, Tavassoli E, Brunsteiner M, Fa M, Arancio O, Petukhov PA, Thatcher GR.

Design, Synthesis, and Optimization of Novel Epoxide Incorporating Peptidomimetics as

Selective Calpain Inhibitors. J Med Chem. 2013 56: 6054-68. PMID: 23834438.

95. Watterson DM, Grum-Tokars VL, Roy SM, Schavocky JP, Bradaric BD, Bachstetter AD,

Xing B, Dimayuga E, Saeed F, Zhang H, Staniszewski A, Pelletier JC, Minasov G,

Anderson WF, Arancio O, Van Eldik LJ. Development of Novel In Vivo Chemical

Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One.

2013 8(6):e66226. PMID: 23840427.

25

*96. Orozco IJ, Koppensteiner P, Ninan I, Arancio O. The schizophrenia susceptibility gene

DTNBP1 modulates AMPAR synaptic transmission and plasticity in the hippocampus of

juvenile DBA/2J mice. Mol Cell Neurosci. 2014 58:76-84. PMID: 24321452

97. Puzzo D, Loreto C, Giunta S, Musumeci G, Frasca G, Podda MV, Arancio O, Palmeri A.

Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice.

Neurobiol Aging. 2014 35: 520-31. PMID: 24112792.

*98 Lee L, Kosuri P, Arancio O. Picomolar Amyloid-β Peptides Enhance Spontaneous

Astrocyte Calcium Transients. J Alzheimers Dis. 2014 38:49-62. PMID: 23948929.

99. Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, Santa-Maria I,

Zimmer M, Aubry S, Steele JW, Kahler DJ, Dranovsky A, Arancio O, Crary JF, Gandy S,

Noggle SA. Characterization and molecular profiling of PSEN1 familial Alzheimer's

disease iPSC-derived neural progenitors. PLoS One. 2014 9:e84547. PMID: 24416243.

*100. Fà M, Staniszewski A, Saeed F, Francis YI, Arancio O. Dynamin 1 is required for

memory formation. PLoS One. 2014 9:e91954. PMID: 24643165.

*101. Ricciarelli R, Puzzo D, Bruno O, Canepa E, Gardella E, Rivera D, Privitera L,

Domenicotti C, Marengo B, Marinari UM, Palmeri A, Pronzato MA, Arancio O, Fedele

E. A novel mechanism for cAMP-mediated memory formation: role of amyloid β. Ann

Neurol. 2014 75: 602-7. PMID: 24591104.

102. Ren H, Yan S, Zhang B, Lu TY, Arancio O, Accili D. Glut4 expression defines an

insulin-sensitive hypothalamic neuronal population. Mol Metab. 2014 3:452-9. PMID:

24944904

103. Origlia N, Criscuolo C, Arancio O, Yan SD, and Domenici L. RAGE inhibition in

microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched

environment. J Neurosci. 2014 34: 8749–8760. PMID: 24966375

*104. Prè D, Nestor MW, Sproul AA, Jacob S, Koppensteiner P, Yamamoto A,

Chinchalongporn V, Zimmer M, Noggle SA, Arancio O. A time course analysis of the

electrophysiological properties of neurons differentiated from human induced Pluripotent

Stem Cells (iPSCs). PLoS One. 2014 9:e103418. PMID: 25072157

105. Guglielmotto M, Monteleone D, Piras P, Valsecchi V, Tropiano M, Ariano S, Fornaro

M, Vercelli V, Puyal J, Arancio O, Tabaton M, Tamagno E. Aβ42 monomers or

oligomers have different effect on autophagy and apoptosis. Authophagy. 2014 10: 1827-

43. PMID: 25136804.

26

*106. Koppensteiner P, Boehm S, Arancio O. Electrophysiological profiles of induced neurons

directly converted from adult human fibroblasts indicate incomplete neuronal conversion.

Cell Reprogr. 2014 16:439-46. PMID: 25437871.

107. Tang G, Gudsnuk K, Kuo SH, Cotrina M, Rosoklija G, Sosunov A, Sonders M, Kanter E,

Castagna C, Yamamoto A, Yue Z, Arancio O, Bradley S. Peterson BS, Champagne F,

Dwork AJ, Goldman J, Sulzer D. Loss of mTOR-dependent macroautophagy

causes autistic-like synaptic pruning deficits. Neuron, 2014 83:1131-43. PMID:

25155956.

108. Yan S, Li Z, Li H, Arancio O, Zhang W. Notoginsenoside R1 increases neuronal

excitability and ameliorates synaptic and memory dysfunction following amyloid

elevation. Sci Rep. 2014 4:6352. doi: 10.1038/srep06352. PMID: 25213453.

*109. Lee L, Dale E, Staniszewski A, Zhang H, Saeed F, Sakurai M, Fa' M, Orozco I,

Michelassi F, Akpan N, Skop H, Arancio O. Regulation of Synaptic Plasticity and

Cognition by SUMO in Normal Physiology and Alzheimer's Disease. Sci Rep. 2014

4:7190. PMID: 25448527.

110. Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G,

Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH,

Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM. Alzheimer's

therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors

mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014 9:e111899.

PMID: 25390692.

111. Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd,

Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R,

Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M,

Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM. Alzheimer's

therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to

specific neuronal receptors is displaced by drug candidates that improve cognitive

deficits. PLoS One. 2014 9:e111898. PMID: 25390368.

112. Nestor MW, Jacob S, Sun B, Prè D, Sproul AA, Hong SI, Woodard C, Zimmer M,

Chinchalongporn V, Arancio O, Noggle SA. Characterization of a subpopulation of

developing cortical interneurons from human iPSCs within serum free embryoid bodies.

AJP-Cell Physiology. 2015 308:C209-19. PMID: 25394470.

113. Roy SM, Grum-Tokars VL, Schavocky JP, Saeed F, Staniszewski A, Teich AF, Arancio

O, Bachstetter AD, Webster SJ, Van Eldik LJ, Minasov G, Anderson WF, Pelletier JC,

Watterson DM. Targeting Human Central Nervous System Protein Kinases: An Isoform

Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's

Disease Mouse Models. ACS Chem Neurosci. 2015 6:666-80. PMID: 25676389

27

114. Kim S, Titcombe RF, Zhang H, Khatri L, Girma HK, Hofmann F, Arancio O, Ziff EB.

Network compensation of cyclic GMP-dependent protein kinase II knockout in the

hippocampus by Ca2+-permeable AMPA receptors. Proc Natl Acad Sci U S A. 2015

112:3122-7. PMID: 25713349.

* 115. Matsuzaki S, Lee L, Knock E, Srikumar T, Sakurai M, Hazrati LN, Katayama T,

Staniszewski A, Raught B, Arancio O, Fraser PE. SUMO1 Affects Synaptic Function,

Spine Density and Memory. Sci Rep. 2015 5: 10730. PMID: 26022678

116. Fang D, Wang Y, Zhang Z, Du H, Yan S, Sun Q, Zhong C, Wu L, Vangavaragu JR, Yan

S, Hu G, Guo L, Rabinowitz M, Glaser E, Arancio O, Sosunov AA, McKhann GM, Chen

JX, Yan SS. Increased neuronal PreP activity reduces Aβ accumulation, attenuates

neuroinflammation and improves mitochondrial and synaptic function in Alzheimer

disease's mouse model. Hum Mol Genet. 2015 24: 5198-210. PMID: 26123488

117. Hue CD, Cho FS, Cao S, Nicholls RE, Vogel Iii EW, Sibindi C, Arancio O, Bass C',

Meaney D, Morrison III B 3rd. Time Course and Size of Blood-Brain Barrier Opening in a

Mouse Model of Blast-Induced Traumatic Brain Injury. J Neurotrauma. 2015 Sep 28.

[Epub ahead of print]. PMID: 26414212

*118 Fà M, Zhang H, Staniszewski A, Saeed F, Shen LW, Schiefer IT, Siklos MI, Tapadar S,

Litosh VA, Libien J, Petukhov PA, Teich AF, Thatcher GR, Arancio O Novel Selective

Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. J Alzheimers Dis.

2015 49:707-21. PMID: 26484927.

119 Luo J, Lee SH, VandeVrede L, Qin Z, Piyankarage S, Tavassoli E, Asghodom RT, Ben

Aissa M, Fà M, Arancio O, Yue L, Pepperberg DR, Thatcher GR. Re-engineering a

neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with

GABAA potentiating activity for use in dementia. BMC Neurosci. 2015 16:67. PMID:

26480871.

* 120 Fá M., Puzzo D., Piacentini R., Staniszewski A., Zhang H., Baltrons M.A., Li Puma

D.D., Chatterjee I., Li J., Saeed F., Berman H.L., Ripoli C., Gulisano W., Gonzalez J.,

Tian H., Costa J.A., Lopez P., Davidowitz E., Yu W.H., Haroutunian V., Brown L.M.,

Palmeri A., Sigurdsson E.M., Duff K.E., Teich A.F., Honig L.S., Sierks M., Moe J.G.,

D’Adamio L., Grassi C., Kanaan N.M., Fraser P.E., Arancio O. Extracellular tau

oligomers produce an immediate impairment of LTP and memory. Sci Rep. 2016 6:

19393. PMCID: PMC4726138

121 Nicholls, R.E., Sontag, J-M., Zhang, H., Staniszewski, A., Yan, S., Kim, C.Y., Yim, M.,

Woodruff, C.M., Arning, E., Wasek, B., Yin, D., Bottiglieri, T., Sontag, E., Kandel, E.R.,

Arancio, O., PP2A methylation controls sensitivity and resistance to β-amyloid–induced

cognitive and electrophysiological impairments. Proc. Natl. Acad. Sci. U S A, In press.

28

*122 Teich AF, Sakurai M, Patel M, Holman C, Saeed F, Fiorito J, Arancio O. PDE5 exists in

Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. J Alzheimers

Dis., In press.

* These publications have been performed in the role of a senior author.

B. Reviews, chapters and editorials

1. MacDermott, AB., Reichling, D., and Arancio, O. Mechanisms underlying excitatory

amino acid-evoked calcium entry in cultured neurons from the embryonic rat spinal cord.

In Y. Ben Ari, ed. Advances in Experimental Medicine and Biology, Excitatory Amino

Acids and Neuronal Plasticity, Plenum press, 1990: 117-124. PMID: 1963736.

2. Arancio, O., and MacDermott, AB. Heterogeneous distribution of excitatory amino acid

receptors on rat spinal cord neurons in culture. In G. Biggio, ed. Treatment of Brain

Ischemia, Pergamon Press, 1990: 67-78.

3. Hawkins, R.D., Zhuo, M., Arancio, O. Nitric oxide and carbon monoxide as possible

retrograde messengers in hippocampal long-term potentiation. In Hiroshi Takagi, Noboru

Toda and R.D. Hawkins, eds. Nitric oxide role in neuronal communication and

neurotoxicity, CRC Press, 1994: 129-147. PMID: 8071665.

4. Hawkins RD, Son H, Arancio O. Nitric oxide as a retrograde messenger during long-

term potentiation in hippocampus. Prog Brain Res 1998; 118:155-172. PMID: 9932440.

*5. Agnihotri, N., Lopez-Garcia, J.C., Hawkins, R.D., *Arancio, O. Morphological changes

associated with long-term potentiation. Histol. and Histopathol. 1998; 13:1155-1162.

PMID: 9810507.

*6. *Arancio, O. Calpain Inhibitors: a Treatment of Alzheimer’s Disease. In Howard M.

Fillit and Alan W. O’Connell, eds Drug Discovery and Development for Alzheimer’s

Disease, 2000, Springer Publishing Company, 2002: 194-203.

*7. Sant’Angelo, A., Trinchese, F., *Arancio, O. Usefulness of behavioral and

electrophysiological studies in transgenic models of Alzheimer’s disease. Neurochem.

Res. 2003 28:1009-15. PMID: 12737525.

*8. Di Rosa, G., Puzzo, D., Sant’Angelo, A., Trinchese, F., *Arancio, O. -synuclein:

between synaptic function and dysfunction. Histol. and Histopathol, 2003 18: 1257-66.

PMID: 12973692.

*9. Ninan, I., *Arancio, O. La plasticité synaptique hippocampique dans la maladie

D’Alzheimer. Alzheimer Actualites (Fondation Ipsen) 2006 184: 9-12.

29

*10. Puzzo, D., Palmeri, A., and *Arancio, O. Involvement of the nitric oxide pathway in

synaptic dysfunction following amyloid elevation in Alzheimer’ Disease. Reviews in the

Neurosciences. Rev Neurosci. 2006;17:497-523. PMID: 17180876.

11. Arancio, O., Chao, MV. Neurotrophins, Synaptic Plasticity and Dementia. Curr. Opinion

Neurobiol. 2007 17: 325-30. PMID: 17419049.

12. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: a potential

target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med.

2007 7:735-42. PMID: 18331231.

13. Puzzo, D., Sapienza, S., Arancio, O., Palmeri, A. Role of phosphodiesterase 5 in synaptic

plasticity and memory. Neuropsychiatric Disease and Treatment 2008 4: 371–387.

14. Serulle Y, Arancio O, Ziff EB. A role for cGMP-dependent protein kinase II in AMPA

receptor trafficking and synaptic plasticity. Channels (Austin). 2008 4:2.

*15. *Arancio, O. PIP2: a new key player in Alzheimer’s disease. Cellscience Reviews 2008.

16. Basavarajappa BS, Nixon RA, Arancio O. Endocannabinoid system: emerging role from

neurodevelopment to neurodegeneration. Mini Rev Med Chem. 2009 9:448-62. PMID:

19356123.

17. Origlia N, Arancio O, Domenici L, Yan SS. MAPK, beta-amyloid and synaptic

dysfunction: the role of RAGE. Expert Rev Neurother. 2009 9:1635-45. PMID:

19903023.

*18. Puzzo D, Arancio O. Amyloid-β Peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis. 2012

Jun 26. [Epub ahead of print] PMID: 22735675

*19. Teich AF, Arancio O. Is the Amyloid Hypothesis of Alzheimer's disease therapeutically

relevant? Biochem J. 2012 446:165-77. PMID: 22891628.

20. Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P. SUMO and Alzheimer's Disease.

Neuromolecular Med. 2013 15:720-36. PMID: 23979993.

*21. Puzzo D, Lee L, Palmeri A, Calabrese G, Arancio O. Behavioral assays with mouse

models of Alzheimer's disease: Practical considerations and guidelines. Biochem

Pharmacol. 2014 88:450-67 PMID: 24462904.

*22. Teich AF, Nicholls RE, Puzzo D, Fiorito J, Purgatorio R, Fa' M, Arancio O. Synaptic

Therapy in Alzheimer's Disease: A CREB-centric Approach. Neurotherapeutics. 2015

12:29-41. PMID: 2557564.

30

23. Puzzo D, Gulisano W, Arancio O, Palmeri A. The keystone of Alzheimer pathogenesis

might be sought in Aβ physiology. Neuroscience. 2015 307:26-36. PMID: 26314631.

*24. Chinchalongporn V, Koppensteiner P, Prè D, Thangnipon W, Bilo L, Arancio O.

Connectivity and circuitry in a dish versus in a brain. Alzheimers Res Ther. 2015 7:44.

eCollection 2015. PMID: 26045718.

*25 Puzzo D, Gulisano W, Palmeri A, Arancio O. Rodent models for Alzheimer's disease

drug discovery.Expert Opin Drug Discov. 2015 10:703-11.PMID: 25927677

*26 Puzzo D, Fiorito J, Purgatorio R, Gulisano W, Palmeri A, Arancio O, Nicholls R.

Molecular Mechanisms of Learning and Memory. Chapter 1 in the book “Genes,

Environment and Alzheimer’s disease” edited by Orly Lazarov and Giuseppina Tesco,

Elsevier Inc. In press.

* These publications have been performed in the role of a senior author.

C. Recent Abstracts (last two years)

1. Jacob S, Nestor M, Sproul A, Paull D, Hong S, Campos B, Alsaffar A, Noggle S, Arancio

O. Characterization of a technique for imaging and recording from human inducible

pluripotent stem cells in serum-free embryoid bodies Soc. Neurosci. Abstr. 2013

415.14/D4.

2. Arancio O, Grum-Tokars VL, Roy SM, Schavocky JP, Bradaric B, Bachstetter AD, Xing

B, Dimayuga E, Saeed F, Zhang H, Staniszewski A, Pelletier JC, Minasov G, Anderson

WF, *L. J. Van Eldik LJ, Watterson D. Development of novel In vivo molecular probes

for CNS serine-threonine protein kinases that modulate synaptic dysfunction. Soc.

Neurosci. Abstr. 2013 523.24/H13.

3. Watterson M, Pelletier J, Anderson W, Arancio O, Van Eldik L. Revisiting protein

kinases as CNS targets: Attenuation of synaptic dysfunction AAIC 2013 P4-313.

4. Longo F, Nguyen TV, Simmons D, Tao Yang, Knowles J, Zhang H, Arancio O, Massa S,

Longo F. Targeting Alzheimer's disease–related mechanisms with p75 ligands. AAIC

2013 S4-02-04.

5. Nicholls RE, Sontag JM, Zhang H, Staniszewski A, Woodruff CM, Yim M, Arning E,

Wasek B, Kim C, Yin D, Bottiglieri T, Sontag E, Kandel ER, Arancio O. The Role of

PP2A Methylation in Beta-amyloid Sensitivity and Resistance. AD/PD 2013. 046.

6. Arancio O, Van Eldik LJ, Saeed F, Bachsetetter A, Schavocky JP, Pelletier JC, Roy SM,

Watterson D. Attenuation of synaptic dysfunction by a novel experimental therapeutic

31

that targets a single kinase present in both neurons and glia. Soc. Neurosci. Abstr. 2014

234.01/X10.